Identifying and prioritizing unanswered clinical questions may help to best allocate limited resources for research associated with the treatment of age-related macular degeneration (AMD).
A ge-related macular degeneration (AMD) is the leading cause of uncorrectable vision loss in adults 50 years and older in the United States. 1 Vision loss due to AMD, which ultimately affects central vision, is associated with poor quality of life and a decreased sense of independence in affected individuals. 2 Similar to clinical measures, outcomes that have been named as important by patients should be validated through research. 3 Patient perspective, clinical expertise, and scientific evidence form the triad of evidence-based medicine; thus these viewpoints should be considered together when setting a research agenda and determining outcomes to be examined in research. 4 Randomized clinical trials (RCTs) and systematic reviews of RCTs are considered to provide the highest level of evidence to determine the effectiveness of clinical interventions. 5 Resources are insufficient to conduct RCTs and systematic reviews on all possible research questions. 6 Thus, establishing a framework for identifying important unanswered clinical questions would help funders and researchers to prioritize trials and systematic reviews to be conducted. The overall objective of this study was to identify and prioritize clinical questions and patient-important outcomes associated with the treatment of AMD by adapting a priority-setting framework used for other eye conditions. [7] [8] [9] [10] [11] The process begins by identifying treatment recommendations from clinical practice guidelines and translating each treatment recommendation into an answerable clinical question. In a previous study, 12 evidence gaps were identified by assessing the evidence cited to support each treatment recommendation and mapping the clinical questions to existing reliable systematic reviews for treatment recommendations extracted from the 2015 American Academy of Ophthalmology (AAO) Preferred Practice Pattern (PPP) for the management of AMD. 13 In this study, multiple stakeholders, including clinical practice guideline developers, health care professionals, and patients, prioritized the importance of research to answer each clinical question in light of the available evidence.
Methods
This study used a modified Delphi process to identify and prioritize clinical research questions and patient-important outcomes associated with the treatment of AMD in 4 steps: (1) derive clinical questions from clinical practice guidelines and specialists in AMD; (2) survey clinical practice guideline developers to identify the most important clinical questions for research to answer; (3) survey retina experts and health care professionals to prioritize the order in which the most important clinical questions should be addressed by research; and (4) survey patients to prioritize the most important clinical questions and outcomes from their perspective ( Figure) . This study was approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, Baltimore, Maryland. Per direction from the institutional review board, the survey included the statement that completing the survey was also providing informed consent. We did not collect identifiable data from any survey participant and all responses remain anonymous. eAppendix 1 in the Supplement includes protocol and amendments.
Step 1: Derive Clinical Questions From Clinical Practice Guidelines and Specialists in AMD
We identified treatment recommendations in the 2014 and 2015 AAO clinical practice guidelines, known as Preferred Practice Pattern (PPP), for management of AMD. 13, 14 Two individuals (B.S.H.
and K.B.L. for 2014 PPP and K.B.L. and S.H. for 2015 PPP) independently reviewed and extracted every statement that could be considered a treatment recommendation published in the PPP guideline. We formulated each recommendation into an answerable clinical question using the PICO (participant, intervention, comparison, and outcome) format. We consulted with AMD specialists (1 member of ACRC and Macula 2017, Neil M. Bressler, MD, and 1 of us, T.W.O.) who had expertise both in the management of AMD and in forming answerable clinical questions to confirm that our restatements were accurate and adding other clinical questions that were not addressed directly in the PPP guideline.
Step 2: Identify Highly Important Clinical Questions
We conducted a 2-round, web-based, cross-sectional, modified Delphi consensus survey. 15 We asked each panel member to assign a rating to each clinical question derived from the PPP on a scale of 0 to 10, with 10 indicating highly important and 0 indicating not important at all. Panel members also had an option to assign a score of "no judgment." At each round, panel members could enter comments and suggest new clinical questions. We administered the first round of the survey in 2 stages because the AAO PPP published an update during the first survey period (January 2015) . From January to February 2015, the 7-member panel rated 46 clinical questions derived from the 2014 AAO PPP on the management of AMD. We used Survey Monkey (http://www.surveymonkey.com) in the first part of round 1; we used Qualtrics (http://www.qualtrics.com) for all subsequent online surveys. One panel member withdrew from the panel between the first and second part of round 1 and was not replaced. In the second part of round 1 (March 2016), the 6-member panel rated 24 additional clinical questions as a continuation of the first round of the survey, 19 derived from the 2015 AAO PPP and 5 contributed by the panel members in the first stage. In the 2 parts of round 1, panel members prioritized a total of 70 clinical questions.
In round 2 of the survey, conducted from June through August 2016, we provided the 6 panel members the median score for each clinical question from the first round of the survey. We asked them to rate the 70 clinical questions again, taking into account the median scores from the first round.
After the second round was completed, we grouped clinical questions into 3 prespecified tiers based on the median scores after the second round (tier 1, median score of 7-10; tier 2, median score of 4-6.9, and tier 3, median score of 0 to 3.9). We considered tier 1 questions to represent highly important clinical research questions. The rationale for asking the panel to identify the most important clinical questions was to reduce the number of clinical questions so that the prioritization surveys could be completed in 15 minutes or less.
Step 3: Prioritize Clinical Questions by Health Care Professionals
To prioritize the tier 1 clinical questions, we surveyed members of the American Society of Retinal Specialists (ASRS) and attendees of the Atlantic Coast Retina Conference (ACRC) and Macula 2017 meetings. Survey participants rated each tier 1 clinical question on a scale of 0 to 10, with 10 indicating the highest priority and 0 indicating not a priority at all (eAppendix 3 in the Supplement). Survey participants also had an option to assign a score of "no judgment" and to submit additional clinical questions important to them. Additionally, we asked survey participants to provide demographic and professional information.
In partnership with ASRS, the survey was announced and first made available at the ASRS exhibitor booth on Retina Subspecialty Day at the AAO Annual Meeting in Chicago, Illinois, on October 14, 2016. The survey was available online via ASRS listserv until December 19, 2016; invitations and reminders to complete the survey were sent to the membership via ASRS's Retina FYI monthly e-newsletter (October, November, and December 2016). The ASRS listserv included 2719 email addresses.
We surveyed attendees of the ACRC and Macula 2017 meeting, held January 5-7, 2017, in Baltimore, Maryland. The survey, administered on paper, included the same questions as those posed to ASRS, with an additional question that asked whether the participant had completed the online survey. We distributed 86 surveys to attendees from the registration table. We collected completed surveys through January 9, 2017.
Step 4: Prioritize Clinical Questions and Outcomes by Patients
The online MD (Macular Degeneration) Support is a nonprofit organization established to educate and support individuals affected by macular degeneration. Survey participants rated each tier 1 clinical question on a scale of 0 to 10, with 10 indicating the highest priority and 0 indicating not a priority at all. In addition to rating the tier 1 clinical questions, survey participants ranked the importance of outcomes related to the management of AMD using 4 categories: most important, moderately important, least important, and unsure (no judgment). We identified the outcomes to be ranked based on common AMD-related outcomes assessed in published RCTs and systematic reviews. 16, 17 We considered outcomes ranked as "most important" by 70% or more respondents as highly important and those scored as "most important" by 15% or fewer respondents as not highly important. 18 We asked participants to record any clinical questions or outcomes of importance to them that were not included in the survey. We also asked broad, nonidentifying questions about the respondents' AMD status, such as stage of AMD. The patient survey was available online from October 13, 2016 , until December 19, 2016 . The MD Support online forum consists of 385 listserv members and 451 people registered for automatic notices on the website. An unknown number of people are registered to both lists; thus, we considered the forum to include a maximum of 836 unique email addresses.
We calculated the median and interquartile range for each clinical question from each prioritization survey. We considered clinical questions with a median score of 7 or higher to represent high-priority clinical questions for research to answer. We compared scores by cohort of stakeholders (ie, ASRS, ACRC and Macula 2017, and MD Support). Data were collected from January 20, 2015, to January 9, 2017. 
Results
In total, we identified 70 clinical questions associated with the management of AMD (eAppendix 1 in the Supplement). Of the 70 clinical questions, 17 involved anti-vascular endothelial growth factor (anti-VEGF) agents; 13 photodynamic therapy; 8 laser photocoagulation; 8 antioxidant vitamin and mineral supplements; and 24 were related to other treatment modalities. The AAO Retina/Vitreous Panel rated 17 of 70 clinical questions (24%) as tier 1 (ie, highly important) ( Figure; eAppendix 2 in the Supplement). No clinical question changed tiers between round 1 and round 2 of the survey. Nine of the 17 tier 1 clinical questions (53%) related to anti-VEGF agents, 4 to antioxidant vitamin and mineral supplements (24%), and 1 each to photodynamic therapy, smoking cessation, self-monitoring, and surgery for cataractineyeswithAMD( Table 1) . Six of the 7 panel members reported no conflicts of interest.
From invitations sent to 2719 email addresses in the ASRS listserv, 106 ASRS members (4%) accessed the online prioritization survey and 90 of 106 members (85%) participated in the survey. Health care professionals assessed the 17 highly important clinical questions and rated 12 of 17 questions (71%) as high priority for research to answer. Nine of the 12 high-priority clinical questions were associated with aspects of anti-VEGF agents. We distributed 86 paper surveys to ACRC and Macula 2017 attendees and 34 of 86 surveys (40%) were returned. None of the ACRC and Macula 2017 respondents reported completing the online survey.
In total, the prioritization surveys were viewed by 192 health care professionals and 124 of 192 professionals (65%) responded to at least 1 survey question.
There were similarities and differences among participants in the ASRS and ACRC and Macula 2017 cohorts ( Table 2) . Most respondents were US-based ophthalmologists specializing in the retina, had affiliation with at least one professional society, had experience working on RCTs, used systematic reviews for making treatment decisions, and reported no conflicts of interest. Many ASRS participants (61 of 90 [68%]) were self-employed or in private practice, whereas most ACRC and Macula 2017 participants (22 of 34 [65%]) were affiliated with academic centers. Eleven percent of ASRS participants (10 of 90) reported that 1% to 25% of their patients had AMD compared with 44% of ACRC and Macula 2017 participants (15 of 34); 54% of ASRS participants (49 of 90) reported that 26% to 50% of their patients had AMD compared with 18% of ACRC and Macula 2017 participants (6 of 34). Among ASRS respondents, 57% (51 of 90) were not members of any formal research group compared with 74% of ACRC and Macula 2017 respondents (25 of 34).
Of the 17 tier 1 clinical questions, there was general agreement among respondents from the health care professional groups surveyed (Table 1) . Both groups rated all 9 of the tier 1 clinical questions associated with anti-VEGF treatments as high priority. Two additional clinical questions were suggested by survey participants: (1) Which types of drug delivery systems are effective and safe? (2) Which interventions are effective and safe for treating or preventing geographic atrophy? Of the 836 email addresses in the MD Support forum, 56 patients (7%) accessed the online prioritization survey and 46 of 56 patients (82%) participated in the survey. Half of the patients who responded had wet AMD (Table 3) . Of 35 respondents with AMD, most had been diagnosed at least 1 year (Figure) , with 12 of 17 questions given a median score of 10 (eAppendix 2 in the Supplement). Survey participants suggested 4 additional clinical questions that were not included in the survey:
1. Is gene therapy (or stem cell therapy) effective in treating AMD? 2. Is the intraocular miniature telescope an effective treatment for AMD? 3. Are cholesterol-lowering diets effective in preventing or reducing AMD-related drusen? 4. What types of education improve living with AMD (eg, online support groups, communication with health care professionals)? Six of 33 outcomes were identified as most important: choroidal neovascularization, development of advanced AMD, any retinal hemorrhage occurring with choroidal neurovascularization, gain of vision, vision loss, and serious ocular events (eg, endophthalmitis). Eight outcomes were scored as not highly important: copper deficiency anemia, cosmetic effects (eg, yellowing of skin), depression, falls, hospitalizations, lung cancer among smokers, visual hallucination, and vitreous floaters ( Table 4) . No additional outcomes were suggested by survey participants.
Discussion
The results of this priority-setting study suggest that research related to anti-VEGF treatments for AMD remains a key area of interest for multiple stakeholder groups. Nine of 17 highly important clinical questions identified by the AAO Retina/Vitreous Panel were associated with aspects of anti-VEGF treatments, all of which were rated as high priority by all prioritization survey cohorts. Previous research evaluating the reliability of systematic reviews of interventions for AMD also showed that anti-VEGF agents were the most common treatment modality evaluated by systematic reviewers.
12 Although many high-quality RCTs and systematic reviews have addressed the effectiveness and safety of intravitreous anti-VEGF injections for AMD, new questions have emerged now that they have become the standard of care for neovascular AMD, concerning how frequently injections should be administered, the long-term (≥10 years) effects of these injections, and other possible drug delivery options. Health care professionals and patients rated clinical questions addressing both effectiveness and safety as highly important. Furthermore, the highly important outcomes identified by patients in this study were balanced between intended effects of AMD treatment (eg, slowing vision loss) and adverse events (eg, retinal hemorrhage). This balance suggests research that examines potential benefits and harms together (eg, trade-off analysis) as an area for future investigation.
Methodologic Considerations
In this study, we evaluated a single method for prioritizing clinical research; another method may have led to other topics given priority. A priority-setting project in the United Kingdom that used a focus group format identified 29 priority questions related to AMD. 19 However, their questions included question types not limited to treatment, such as "What is the cause of AMD?" and questions too broad for an RCT to address, such as "Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?" Our project was designed to include and prioritize only clinical questions for specific treatments. c Multiple answers allowed; total percentages may add to more than 100.
d No response for 10 of 46 survey participants.
Research Original Investigation Clinical Questions and Patient-Important Outcomes and the Treatment of Age-Related Macular Degeneration
As part of the study design, we asked the AAO Retina/Vitreous Panel to narrow the list of 70 clinical questions that we identified to a shortened list of highly important (tier 1) clinical questions. The rationale was to reduce the number of clinical questions for the larger groups to prioritize. However, even with a shortened survey, the response rate was low for all groups surveyed.
Patients rated all 17 clinical questions identified as highly important by the AAO Retina/Vitreous Panel as high priority, compared with 12 of 17 rated as high priority by both health care professional groups. When asked to rank the importance of outcomes by allocating outcomes into 1 of 4 categories, patients distinguished 6 highly important outcomes and 8 not so important outcomes among 33 outcomes assessed. Other patient-focused research has shown that patients tend to score all items as high priority when using rating scales, such as Likert scales. 20 For prioritization research, asking participants to rank items rather than rating them independently may elicit clear patient preferences. We identified at least 12 high-priority clinical research questions. Survey participants suggested additional areas of interest, To address this issue, we consulted with members of the AAO Retina/Vitreous Panel to add relevant clinical questions to our initial set and provided survey participants opportunities to suggest additional research questions at each stage of the process.
Conclusions
The 6 highly important outcomes targeted by patients should be considered in the discussion of core outcome sets for studies that evaluate the treatment of AMD. Choroidal neovascularization and visual acuity are outcomes that have been noted frequently in outcome research related to AMD; however, retinal hemorrhage has been considered less frequently by clinicians and researchers. 17 the results of a prioritization process aiming to build on the existing American Academy of Ophthalmology Preferred Practice Patterns (AAO PPP), 2 which were first published in 2015 and provided guidance on the clinical management of age-related macular degeneration (AMD). Guideline developers as well as a large number of patients and health care professionals were surveyed to rank the importance of existing recommendations, which were restated as answerable questions and add new questions to fill gaps in previous guidelines. Clinical and patient-centered outcomes related to these questions were also extracted and assessed.
Prioritizing questions for clinical guidelines depends on the setting and the perspective assumed by the developers. In the present study, 1 the researchers adopted an established methodology that preserves the work already done in the previous AAO PPPs and broadens the panel to augment it. All panels agreed on the high priority of comparative effectiveness questions regarding the efficacy and safety of different antiangiogenic drugs. For example, one of the top ranked clinical questions for research was "Are intravitreous injections of anti-VEGF [vascular endothelial growth factor] agents effective treatments for neovascular AMD?" This raises the interesting issue as to whether an additional metric of clinical uncertainty, although perhaps difficult to measure, would further refine the development of research priorities. Clinicians did not completely agree with patients' representatives, most of whom were affected by AMD, on the priority of a few questions related to antioxidant and mineral supplementation, and they also disagreed regarding the importance of sunlight protection after photodynamic therapy, the use of which is currently limited to patients with polypoidal choroidal vasculopathy. As expected, vision gain/loss and the development of advanced forms of AMD were among the most important outcomes. Surprisingly, depression and falls were considered only moderately important, although they are commonly included in models investigating the cost-effectiveness of antiangiogenic drugs because they have both a large impact on quality-adjusted life years and costs at the population level. Research Aims:
The overall aim of this study is to test a framework for setting priorities for systematic reviews and RCTs related to treatment of age related macular degeneration (AMD). In this study, we will translate statements in the American Academy of Ophthalmology (AAO) clinical practice guideline for management of AMD into answerable clinical questions and map the questions to existing, reliable systematic reviews. We will partner with clinical practice guideline developers, retina experts, healthcare professionals, and patients to prioritize a research agenda for AMD.
By identifying and assessing the available evidence, and the important clinical questions, we aim to provide reliable information to clinicians, researchers, and policymakers; identify where evidence gaps exist; and prioritize important clinical questions for research to answer.
Methods:

1) Extraction of guideline recommendations
Two individuals will independently review and extract every statement that could be considered a recommendation, published in the AAO's Preferred Practice Patterns (PPPs) related to the management of AMD (AAO 2015). We will restate each recommendation as an answerable clinical question. We will consult with AMD specialists who have expertise both in the management of AMD and in forming answerable clinical questions to confirm that our restatements are accurate. The restated clinical questions will constitute a preliminary list of priorities for systematic reviews and clinical trials to address. We will refine this list in subsequent cross sectional surveys.
2) Survey to identify highly important clinical questions: Survey of the American Academy of Ophthalmology Retina/Vitreous Panel
The purpose of surveying the AAO Retina/Vitreous Panel will be to identify highly important clinical questions to be prioritized. Initial discussions with professional associations and patient groups suggested that their membership would be more likely to respond and complete the surveys if the number of questions could be reduced so that the survey could be completed in 15 minutes or fewer. Members of the AAO Retina/Vitreous Panel will score all clinical questions derived in the first step and we will use their responses to form the shortened list of highly important clinical questions to be prioritized.
We will conduct a two round web based cross sectional modified "Delphi" consensus survey ). We will ask survey participants electronically, using email and the Internet, to score the list of research questions we derived from the AAO's PPP on the management of AMD. The invitation to participate will be sent by an AAO designee and will include the consent to participate (see "Description of the Consent Process"). We will ask participants to score each clinical question on a scale of 0 to 10, with a score of 10 indicating that they view the clinical question as highly important; a score of 0 indicates that they view the clinical question as not important at all. If the participant feels unqualified to rate a particular clinical question, they may select 'no judgment'. There will be space for comments, questions and nomination of items not included in the list. Respondents will be given 4 weeks total to respond to Round One of the survey. After the initial request, an email reminder will be sent at the end of week 1, week 2, week 3, and 2 days prior to the end of week 4.
In Round Two of the survey we will provide each respondent with the group summary measure (median) for each clinical question asked in Round One and ask the Panel to score additional clinical questions suggested by respondents in Round One. Respondents will be given the opportunity to re score each item in light of ratings and comments from the previous round. Respondents will be given 4 weeks total to respond to this round of the survey. After the initial request, an email reminder will be sent at the end of week 1, week 2, week 3, and 2 days prior to the end of week 4.
The highest scored clinical questions will represent the highly important clinical questions to be prioritized. We will include the highest scored 10 15 clinical questions, with median scores of at least 7 or higher, in the prioritization surveys. Lower scored clinical questions, considered as moderately important (median at least 4) or not important (median less than 4), will not be included in the prioritization surveys.
3) Survey of healthcare professionals to prioritize clinical questions: Survey of the American Society of Retina Specialists
Using the survey results from the AAO Retina/Vitreous Panel, we will ask members of the American Society of Retinal Specialists (ASRS) to prioritize the order in which the highly important clinical questions should be answered.
The invitation to participate in the survey will be sent by an ASRS designee and will include the consent to participate (see "Description of the Consent"). We will ask participants to score each clinical question on a scale of 0 to 10, with a score of 10 indicating that they view the clinical question as high priority; a score of 0 indicates that they view the clinical question as not a priority. If the participant feels unqualified to score a particular clinical question, they may select 'no judgment'. There will be space for comments, questions and nomination of items not included in the list. Respondents will be given 4 weeks total to respond to the survey. After the initial request, an email reminder will be sent at the end of week 1, week 2, week 3, and 2 days prior to the end of week 4.
Additionally, we will request survey participants to provide demographic and other information such as occupation/field, specialty, and place of employment (e.g. government, industry, academia, other), experience in clinical trials/systematic reviews (see draft survey). These data will be examined for possible association with the level of importance assigned if sufficient data are available. We will not collect identifiable data and expect that all responses will remain anonymous.
4) Survey of patients to prioritize clinical questions and outcomes: Survey of MD Support
We will ask members of MD Support (www.mdsupport.org), an online patient group for macular degeneration, to prioritize the order in which the highly important clinical questions should be answered by research. The clinical questions will be reworded to lay language, in collaboration with the Director of MD Support, and we will include definitions of clinical terms to make the survey questions clear to non healthcare professionals. Additionally, we will ask for their assistance in identifying patient important outcomes for systematic reviews and RCTs related to management of AMD. We will derive the list of outcomes for patients to assess from common outcomes assessed in research related to AMD ). We will ask each survey participant demographic and other information, such as having early or advanced stage AMD (i.e. advanced stage = previously received laser or injections in the eye to treat AMD).
5) Sample size a. Survey of the American Academy of Ophthalmology's Retina/Vitreous Panel
The size of the AAO Retina/Vitreous Panel varies from 6 to 8 individuals. Because this effort has full collaboration with the AAO, we estimate that all active Panel members will participate in each of the two rounds of the survey.
b. Survey of the American Society of Retina Specialists
We aim to invite about 400 ASRS members. We estimate that a minimum of 25% will participate in the online surveys.
c. Survey of patient and consumer panels
MD Support's online forum consists of about 400 members. We will invite all members with active email addresses to participate in the online survey and estimate that a minimum of 25% with AMD will participate in the online survey.
6) Analysis and Reporting a. Statistical Plan
We will calculate summary statistics (mean, standard deviation, median, and inter quartile range) of scores for each clinical question for each survey. We will compare scores by groups of stakeholders, for example healthcare professionals versus patients.
b. Dissemination
We will report our results in a journal article as well as other methods of dissemination (email to survey partners, Twitter, etc.). We will assess the utility of the project by obtaining feedback from CEV editors and authors conducting systematic reviews.
7) Ethical considerations (IRB #2709; exemption status) a. Inclusion and Exclusion Criteria
The inclusion criterion is to be a member of the respective group that is being asked to complete each specific survey (AAO Retina/Vitreous Panel, ASRS, or MD Support). Consumer patient stakeholders from MD Support will have self reported AMD or care for a person with AMD to be eligible for analysis.
b. Gender, Age and Locale
We will not exclude participants on the basis of gender, age, or nationality.
c. Recruitment Process
For all surveys, our collaborating partners (AAO, ASRS, and MD Support) will invite participation by email.
d. Risk/Benefits
Description of Risks: There is no foreseeable physical risk to survey participants. Participation in the survey may involve a loss of privacy and a commitment of time.
Description of Measures to Minimize Risks: We will pilot test each round of the survey to provide participants with an estimate of the time it will take to complete. We will ensure participant anonymity and confidentially of responses. Only survey moderators will have access to the anonymous individual survey results. We will report results in an aggregate form without personal identifiers (see "Confidentiality Assurance").
Description of Potential Benefits: By providing their opinions on the importance of a series of clinical questions about AMD, survey participants will contribute to establishing a framework for setting priorities for new systematic reviews and RCTs.
Description of Level of Research Burden: We anticipate that the time commitment for each survey will vary, decreasing with each round. No survey should take more than 30 minutes to complete.
e. Compensation
There will be no monetary compensation for participating in any survey, although each group participating will be thanked and acknowledged in publications and on the CEV website.
f. Description of the Consent Process
For all surveys, the initial invitation will contain a description of the research we are conducting. Invitees will be given a total of 4 weeks to consider whether they will participate. An email reminder will be sent at the end of each of the 4 weeks that the survey is active. We will consider a response to the survey as evidence of consent to participate. We will consider the invitee as declining participation if s/he sends a declining email or if s/he does not respond to the survey after four weeks.
g. Data Security
All survey invitations and reminders will be sent by the partnering groups; none by CEV.
CEV will not solicit the contact information of members from our partner groups; however, email, mail, or phone correspondence from a survey participant to CEV moderators may include information that would enable the moderators to know who the participant is. In any case, participant names will not be used on any survey instrument or data file. We will report results in an aggregate form without personal identifiers.
We will store paper forms in an office building that has very good external security (615 N. Wolfe Street Baltimore, MD 21205). The building has a 24 hour manned security desk, and photo ID is required to get in. We will store the electronic data file on a password protected server. We will back up data files on a regular basis with a CD ROM version stored off site.
8) Protocol amendments
In August 2016, after receiving the Panel's Round 2 survey responses, we increased the number of highly important clinical questions to be prioritized from 10 15 to 17 based on the median score of 7 or higher.
